Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir

Alinda G Vos, Matthew F Chersich, Kerstin Klipstein-Grobusch, Peter Zuithoff, Michelle A Moorhouse, Samanta T Lalla-Edward, Andrew Kambugu, N Kumarasamy, Diederick E Grobbee, Roos E Barth, Willem D Venter, Alinda G Vos, Matthew F Chersich, Kerstin Klipstein-Grobusch, Peter Zuithoff, Michelle A Moorhouse, Samanta T Lalla-Edward, Andrew Kambugu, N Kumarasamy, Diederick E Grobbee, Roos E Barth, Willem D Venter

Abstract

Background: HIV infection and antiretroviral treatment are associated with changes in lipid levels, insulin resistance and risk of cardiovascular disease (CVD). We investigated these changes in the first 96 weeks of treatment with low-dose stavudine or tenofovir regimens.

Methods: This is a secondary analysis of a double blind, randomised controlled trial performed in South-Africa, Uganda and India comparing low-dose stavudine (20 mg twice daily) with tenofovir in combination with efavirenz and lamivudine in antiretroviral-naïve adults (n = 1067) (Clinicaltrials.gov, NCT02670772). Over 96 weeks, data were collected on fasting lipids, glucose and insulin. Insulin resistance was assessed with the HOMA-IR index and 10-year CVD risk with the Framingham risk score (FRS). A generalized linear mixed model was used to estimate trends over time.

Results: Participants were on average 35.3 years old, 57.6% female and 91.8% Black African. All lipid levels increased following treatment initiation, with the sharpest increase in the first 24 weeks of treatment. The increase in all lipid subcomponents over 96 weeks was higher among those in the stavudine than the tenofovir group. Insulin resistance increased steadily with no difference detected between study groups. FRS rose from 1.90% (1.84-1.98%) at baseline to 2.06 (1.98-2.15%) at week 96 for the total group, with no difference between treatment arms (p = 0.144). Lipid changes were more marked in Indian than African participants.

Conclusion: Lipid levels increased in both groups, with low-dose stavudine resulting in a worse lipid profile compared to tenofovir. Insulin resistance increased, with no difference between regimens. CVD risk increased over time and tended to increase more in the group on stavudine. The low CVD risk across both arms argues against routine lipid and glucose monitoring in the absence of other CVD risk factors. In high risk patients, monitoring may only be appropriate at least a year after treatment initiation.

Keywords: Cardiovascular disease risk; HIV; India; South Africa; Stavudine; Tenofovir; Uganda.

Figures

Fig. 1
Fig. 1
Trends in estimated marginal mean lipid levels in each study group. HDL-C high density lipoprotein cholesterol, LDL-C low densiy lipoprotein cholesterol, Total-C total cholesterol
Fig. 2
Fig. 2
Trends in estimated marginal mean levels of indicators of insulin resistance
Fig. 3
Fig. 3
Trend in estimated marginal mean levels of 10-year CVD risk

References

    1. GBD 2016 Causes of Death Collaborators Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151–1210. doi: 10.1016/S0140-6736(17)32152-9.
    1. Dillon DG, Gurdasani D, Riha J, Ekoru K, Asiki G, Mayanja BN, et al. Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol. 2013;42(6):1754–1771. doi: 10.1093/ije/dyt198.
    1. Kingery JR, Alfred Y, Smart LR, Nash E, Todd J, Naguib MR, et al. Short-term and long-term cardiovascular risk, metabolic syndrome and HIV in Tanzania. Heart. 2016;102(15):1200–1205. doi: 10.1136/heartjnl-2015-309026.
    1. Nduka CU, Stranges S, Sarki AM, Kimani PK, Uthman OA. Evidence of increased blood pressure and hypertension risk among people living with HIV on antiretroviral therapy: a systematic review with meta-analysis. J Hum Hypertens. 2016;30(6):355–362. doi: 10.1038/jhh.2015.97.
    1. Nou E, Lo J, Grinspoon SK. Inflammation, immune activation, and cardiovascular disease in HIV. AIDS. 2016;30(10):1495–1509. doi: 10.1097/QAD.0000000000001109.
    1. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Internal Med. 2013;173(8):614–622. doi: 10.1001/jamainternmed.2013.3728.
    1. Zanni MV, Schouten J, Grinspoon SK, Reiss P. Risk of coronary heart disease in patients with HIV infection. Nat Rev Cardiol. 2014;11(12):728–741. doi: 10.1038/nrcardio.2014.167.
    1. Dube MP, Cadden JJ. Lipid metabolism in treated HIV Infection. Best Pract Res Clin Endocrinol Metab. 2011;25(3):429–442. doi: 10.1016/j.beem.2011.04.004.
    1. Clotet B, Negredo E. HIV protease inhibitors and dyslipidemia. AIDS Rev. 2003;5(1):19–24.
    1. Stein JH. Dyslipidemia in the era of HIV protease inhibitors. Prog Cardiovasc Dis. 2003;45(4):293–304. doi: 10.1053/pcad.2003.3.
    1. Sinxadi PZ, McIlleron HM, Dave JA, Smith PJ, Levitt NS, Haas DW, et al. Plasma efavirenz concentrations are associated with lipid and glucose concentrations. Medicine (Baltimore) 2016;95(2):e2385. doi: 10.1097/MD.0000000000002385.
    1. Fleischman A, Johnsen S, Systrom DM, Hrovat M, Farrar CT, Frontera W, et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab. 2007;292(6):E1666–E1673. doi: 10.1152/ajpendo.00550.2006.
    1. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292(2):191–201. doi: 10.1001/jama.292.2.191.
    1. George JA, Venter WD, Van Deventer HE, Crowther NJ. A longitudinal study of the changes in body fat and metabolic parameters in a South African population of HIV-positive patients receiving an antiretroviral therapeutic regimen containing stavudine. AIDS Res Hum Retroviruses. 2009;25(8):771–781. doi: 10.1089/aid.2008.0308.
    1. Mouton JP, Cohen K, Maartens G. Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen. Expert Rev Clin Pharmacol. 2016;9(11):1493–1503. doi: 10.1080/17512433.2016.1221760.
    1. World HO. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010 revision. 2010.
    1. Venter WDF, Kambugu A, Chersich MF, Becker S, Hill A, et al. Efficacy and safety of tenofovir disoproxil fumarate versus low-dose stavudine over 96 weeks: a multi-country randomised, non-inferiority trial. J Acquir Immune Defic Syndr. 2018 doi: 10.1097/QAI.0000000000001908.
    1. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–1495. doi: 10.2337/diacare.27.6.1487.
    1. Framingham Heart Study10-year CVD risk score. . Accessed 27 April 2018.
    1. Roy J. Applied Longitudinal Analysis, Second Edition, by G. M. Fitzmaurice, N. M. Laird, and J. H. Ware. J Biopharm Stat. 2013;23(2):491–492. doi: 10.1080/10543406.2012.755660.
    1. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74(5):1045–1052.
    1. Dave JA, Levitt NS, Ross IL, Lacerda M, Maartens G, Blom D. Anti-retroviral therapy increases the prevalence of dyslipidemia in South African HIV-infected patients. PLoS ONE. 2016;11(3):e0151911. doi: 10.1371/journal.pone.0151911.
    1. Miedema F, Hazenberg MD, Tesselaar K, van Baarle D, de Boer RJ, Borghans JA. Immune activation and collateral damage in AIDS pathogenesis. Front Immunol. 2013;26(4):298.
    1. Funderburg NT, van Mehta NN. Lipid abnormalities and inflammation in HIV inflection. Curr HIV/AIDS Rep. 2016;13(4):218–225. doi: 10.1007/s11904-016-0321-0.
    1. Liu E, Armstrong C, Spiegelman D, Chalamilla G, Njelekela M, Hawkins C, et al. First-line antiretroviral therapy and changes in lipid levels over 3 years among HIV-infected adults in Tanzania. Clin Infect Dis. 2013;56(12):1820–1828. doi: 10.1093/cid/cit120.
    1. Nduka C, Sarki A, Uthman O, Stranges S. Impact of antiretroviral therapy on serum lipoprotein levels and dyslipidemias: a systematic review and meta-analysis. Int J Cardiol. 2015;15(199):307–318. doi: 10.1016/j.ijcard.2015.07.052.
    1. Tang Q, Li X, Song P, Xu L. Optimal cut-off values for the homeostasis model assessment of insulin resistance (HOMA-IR) and pre-diabetes screening: developments in research and prospects for the future. Drug Discov Ther. 2015;9(6):380–385. doi: 10.5582/ddt.2015.01207.
    1. Meeks KA, Stronks K, Adeyemo A, Addo J, Bahendeka S, Beune E, et al. Peripheral insulin resistance rather than beta cell dysfunction accounts for geographical differences in impaired fasting blood glucose among sub-Saharan African individuals: findings from the RODAM study. Diabetologia. 2017;60(5):854–864. doi: 10.1007/s00125-017-4216-4.
    1. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, et al. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother. 2007;8(5):679–688. doi: 10.1517/14656566.8.5.679.
    1. McComsey GA, Lo Re V, 3rd, O’Riordan M, Walker UA, Lebrecht D, Baron E, et al. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: a randomized, controlled study. Clin Infect Dis. 2008;46(8):1290–1296. doi: 10.1086/529384.
    1. Quercia R, Roberts J, Martin-Carpenter L, Zala C. Comparative changes of lipid levels in treatment-naive, HIV-1-infected adults treated with dolutegravir vs. efavirenz, raltegravir, and ritonavir-boosted darunavir-based regimens over 48 weeks. Clin Drug Investig. 2015;35(3):211–219. doi: 10.1007/s40261-014-0266-2.
    1. Anand SS, Yusuf S, Vuksan V, Devanesen S, Teo KK, Montague PA, et al. Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE) Indian Heart J. 2000;52(7 Suppl):S35–S43.
    1. Frank AT, Zhao B, Jose PO, Azar KM, Fortmann SP, Palaniappan LP. Racial/ethnic differences in dyslipidemia patterns. Circulation. 2014;129(5):570–579. doi: 10.1161/CIRCULATIONAHA.113.005757.
    1. Patel SA, Shivashankar R, Ali MK, Anjana RM, Deepa M, Kapoor D, et al. Is the “South Asian phenotype” unique to South Asians?: comparing cardiometabolic risk factors in the CARRS and NHANES studies. Glob Heart. 2016;11(1):89-96.e3.
    1. Friis-Moller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol. 2016;23(2):214–223. doi: 10.1177/2047487315579291.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner